aid: elektrofi accessModel: pricing: unknown onboarding: unknown trial: false try_now: false public: false label: Unknown confidence: low source: [] generated: '2026-07-22' method: derived image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/elektrofi.png name: Elektrofi description: >- Elektrofi is a Boston-based biopharmaceutical formulation technology company reinventing how biologic therapies are delivered to patients. Its Hypercon ultra-high-concentration microparticle platform and Elektroject process turn monoclonal antibodies, therapeutic proteins, and other large-molecule drugs into stable, syringe-injectable formulations suited to small-volume, at-home subcutaneous self-administration instead of intravenous infusion. The company has partnered with Eli Lilly and Janssen Biotech (Johnson & Johnson) on multi-target drug-delivery collaborations, and was acquired by Halozyme Therapeutics in November 2025. Elektrofi is a biotechnology company and does not publish a public developer API; this API Evangelist profile tracks it as a company entity within the network. url: https://raw.githubusercontent.com/api-evangelist/elektrofi/refs/heads/main/apis.yml x-type: company x-source: vc-portfolio x-backed-by: - general-catalyst x-tier: stub x-tier-reason: portfolio-lead x-acquired-by: halozyme specificationVersion: '0.20' created: '2026-07-17' modified: '2026-07-19' tags: - Company - Biotechnology - Pharmaceuticals - Drug Delivery - Biologics - Formulation Technology - Subcutaneous - Life Sciences apis: [] common: - type: DomainSecurity url: security/elektrofi-domain-security.yml - type: Website url: https://www.elektrofi.com/ - type: About url: https://www.elektrofi.com/about - type: Blog url: https://www.elektrofi.com/news - type: Team url: https://www.elektrofi.com/team maintainers: - FN: Kin Lane email: kin@apievangelist.com - FN: APIs.json email: info@apis.io x-enrichment: date: '2026-07-19' status: backfilled pass: local-v1 note: backfilled from .gitignore signal + verified work evidence